A tighter archive for life-science signals.
Search once, then narrow by source or topic.
5 FDA drug approvals to watch in 2026
5 FDA drug approvals to watch in 2026
PharmaVoice’s Crystal Ball: Market and policy forces shaping the industry
PharmaVoice’s Crystal Ball: Market and policy forces shaping the industry
3 of China’s most innovative pharma companies
3 of China’s most innovative pharma companies
Beyond Botox: AbbVie’s push for broader gains in neurotoxin R&D
Don't miss the most important voices in pharma Let PharmaVoice's free newsletter keep you informed on what industry leaders are saying, straight from your inbox. By sig...
Biopharma CEO optimism is wavering in the U.S.
Biopharma CEO optimism is wavering in the U.S.
Biogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth
Biogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth
The leading GLP-1 contenders in pharma’s race for an obesity pill
The leading GLP-1 contenders in pharma’s race for an obesity pill
3 key takeaways from the FDA’s new animal testing guidance
3 key takeaways from the FDA’s new animal testing guidance
How the FDA could soon upend vaccine trials
How the FDA could soon upend vaccine trials
5 CDER directors in one year? Turnover threatens ‘institutional memory’ at US health agencies.
5 CDER directors in one year? Turnover threatens ‘institutional memory’ at US health agencies.
After years of debate, the Biosecure Act could be headed for Trump’s desk
After years of debate, the Biosecure Act could be headed for Trump’s desk
Amylyx pins its next hopes on a niche drug in the obesity space
Amylyx pins its next hopes on a niche drug in the obesity space
Pharma’s top deals in 2025
Pharma’s top deals in 2025
Will 2026 be pharma’s M&A breakout year?
Will 2026 be pharma’s M&A breakout year?
Another genetic testing company? Why a different approach could boost drug predictions and R&D.
Another genetic testing company? Why a different approach could boost drug predictions and R&D.
How Lilly uses Big Pharma heft to lift up-and-coming biotechs
How Lilly uses Big Pharma heft to lift up-and-coming biotechs
Standout drug approvals in 2025
Standout drug approvals in 2025
Unifying life sciences insights to accelerate enterprise value
Unifying life sciences insights to accelerate enterprise value
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page